Browse by Day Archive
Mead Johnson wins US federal bellwether trial over preterm infant formula Enfamil
09/01/2026 10:22am
A U.S. federal jury sided with Reckitt Benckiser's Mead Johnson on Monday in a test trial over claims the company's Enfamil infant formula for preterm babies caused necrotizing enterocolitis (NEC), a dangerous bowel disease.
Alumis eyes late-stage lupus study despite trial miss
09/01/2026 7:15am
Alumis said on Tuesday it plans to advance its experimental drug for a type of immunity-related condition in a smaller subset of patients, even after the treatment failed to meet the main goal of a mid-stage trial.
Oncology firm Novocure says cyberattack exposed US patient records
09/01/2026 5:54am
Oncology company Novocure said on Tuesday a cybersecurity incident involving unauthorized access to certain information systems in mid-August exposed internal records of more than 1,400 U.S. patients.
Roche signs global licensing pact for Simcere's experimental blood cancer drug
09/01/2026 5:03am
Switzerland's Roche will pay $75 million upfront to Simcere Pharmaceutical Group for rights to an experimental blood cancer drug, the Chinese drugmaker said Tuesday.
Medtronic boosts fiscal 2027 forecasts on heart device demand
09/01/2026 4:48am
Medtronic raised its fiscal 2027 revenue growth outlook and the lower end of its profit forecast on Tuesday, banking on strong demand for its heart devices used in complex cardiovascular procedures.
Novartis MS pill beats older drug in trials, boosts pipeline hopes
09/01/2026 1:13am
(Corrects paragraph 12 to say remi is approved to treat only one skin condition, not two)
Novartis MS pill beats older drug in trials, boosts pipeline hopes
09/01/2026 1:13am
Swiss drugmaker Novartis said on Tuesday its oral drug remibrutinib outperformed an older treatment in reducing relapses in patients with a form of multiple sclerosis, boosting hopes the medicine could become a blockbuster product.
GSK to advance mRNA flu vaccine to late-stage trial
09/01/2026 12:14am
(Corrects paragraph 4 to clarify that GSK plans to start more than 20, not 25, late-stage trials in 2026)
